Intraperitoneal chemotherapy with mitoxanthrone in ovarian cancer

Tumori

Volumn 83, Issue 5, 1997, Pages 837-840

  Le Donne, Maria ^a   Messina, Giovanna ^a   Buda, Concetta ^a   Corrado, Francesco ^a   Pettineo, Giuseppe ^b   Salimbeni, Vincenzino ^b   Irato, Stefano ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Intraperitoneal administration; Mitoxanthrone; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; MITOXANTRONE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; INTESTINE PERFORATION; INTRAPERITONEAL DRUG ADMINISTRATION; OVARY CANCER; PERITONITIS;

EID: 0031426214     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169708300513     Document Type: Article

References (31)

1. Alberts D.S., Young L., Masan N.L., Salmon S.E.: In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin. Oncol., 12 (suppl. 4): 38-45, 1985.
2. Alberts D.S., Surwit E.A., Peng Y.M.: Phase I clinical and pharmacokinetic study of mitoxanthrone given to patients by intraperitoneal administration. Cancer Res., 48: 5874-5877, 1990.
3. Alberts D.S., Liu P.Y., Mannigan E.V.: Phase III study of intraperitoneal (IP) cisplatin (CDDP), intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer. ASWOG-GOG-ECOC Intergroup study (INT 0051). Proc. Am. Soc. Clin. Oncol., 14: 273 (Abst. 760), 1995.
4. Blochl-Daum B., Eichler H.G., Rainer H.: Escalating dose regimen of intraperitoneal mitoxanthrone: phase I study-clinical and pharmacokinetic evaluation. Eur. J. Cancer Clin. Oncol., 24: 1133-1138, 1988.
5. Davidson S.A., Rubin S.C., Markman M.: Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol. Oncol., 41: 101, 1991.
6. Dedrick R., Myers C., Bungey P.: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep., 62: 1-11, 1978.
7. de Jong R.S., Willemse P.M., Boonstra M., de Vries E.G.E., van der Graaf W.T.A., Sleyfer D.T.L., van der Zee A.G.J., Mulder N.H.: Phase II study of intraperitoneal cisplatin plus systemic etoposide as second line treatment in patients with small volume residual ovarian cancer. Eur. J. Cancer, 31A: 709-713, 1995.
8. Frasci G., Pacelli R., Scala S., Facchini G., Rinaldi L., Tinessa V., Bianco A.R., laffaioli R.V.: Intraperitoneal mitoxanthrone via temporary catheter in patients with ovarian cancer toxicity and feasibility evaluation. Advances in Therapy, 7: 121-134, 1990.
9. Griffiths C.T.: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl. Cancer Inst. (Monogr.), 42: 101, 1975.
10. Howell S.B., Kirmani S., Lucas W.E., Zimm S., Goel R., Kim S., Morton M.C., McVey L., Morris J., Weiss R.J.: A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. J. Clin. Oncol., 8: 137-145, 1990.
11. Lawton F., Blackledge G., Mould J., Latief T., Watson R., Chewtiyawardana A.D.: Phase II study of mitoxanthrone in epithelial ovarian cancer. Cancer Treat. Rep., 71: 627-629, 1987.
12. Los G., Mutsaerts P.M.A., Van der Vijgh W.J.: Platinum distribution in intraperitoneal tumors after intraperitoneal or intravenous chemotherapy (Abst.). Proc. ASCO, 160, 1987.
13. MacKintosh J., Buckley C.M., Tindall V.R., Lind M.J., Anderson M., Crowther D.: The role of post-operative alkylating agent therapy in early-stage epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 96: 353-357, 1989.
14. Markman M., Hakes T., Reichman B., Lewis J.L., Rubin S., Jones W., Almadrones L., Hoskins W.: Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. J. Clin. Oncol., 9: 204-210, 1991.
15. Markman M., George M., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadrones L., Lewis J.L.: Phase 2 trial of intraperitoneal mitoxanthrone in the management of refractory ovarian carcinoma. J. Clin. Oncol., 8: 146-150, 1990.
16. Markman M.: Intraperitoneal chemotherapy. In: Markman M., and Hoskins W.J. Eds., Cancer of the ovary, pp. 317-325, Raven Press, New York, 1993.
17. Markman M., Rowinski E., Maker T.: Phase I trial of intraperitoneal taxol. A Gynecologic Oncology Group Study. J. Clin. Oncol., 10: 1485-1491, 1992.
18. Maruyama M., Takamatsu H., Sugano N., Katada M., Ebuchi M.: Complications in the intraperitoneal chemotherapy with the implantable intraperitoneal port and the strategy for the prevention of the complication. Gan To Kagaku Ryoho, 22: 1469-1472, 1995.
19. Menczer J.: Use of the verress needle for instillation of intraperitoneal chemotherapy. Gynecol. Oncol., 59: 249-250, 1995.
20. Muggia F., Liv P.Y., Alberts D.S., Terada K., Belt R.J., Schmidt M.J., Pollack T.W., Weiser E.B., Blayney D., Wallace D.: Elevated serum Ca-125: an adverse prognostic factor for survival in epithelial ovarian cancer (EOC) with minimal residual disease after second look laparotomy (SLL). Proc. Ann. Meet. Am. Soc. Clin. Oncol., 14: A750, 1995.
21. Neijt J.P., Ten Bokkel Huinink W.W., Van der Burg M.E.L.: Randomized trial comparing two combination chemotherapy regimens (CHAP. 5, VCP) in advanced ovarian carcinoma. J. Clin. Oncol. 5: 1157-1168, 1987.
22. Ozols R.F.: Treatment of ovarian cancer - current status. Sem. Oncol., 21 (suppl. 2): 1-9, 1994.
23. Petru E., Lahounsen M., Tamussino K., Pickel H., Stettner H.: Prognostic volume in stage III ovarian cancer patients undergoing adjuvant cytotoxic chemotherapy. Baillieres Clin. Obstet. Gynaecol., 3: 109-117, 1989.
24. Piccart M.J.: Intraperitoneal chemotherapy: technical experience at five institutions. Sem. Oncol., 12 (suppl.): 90, 1985.
25. Piver M.S., Fanning J., Sprance M.E.: Five year survival for cisplatin based chemotherapy versus single-agent melphalan in patients with advanced ovarian cancer and optimal debulkine surgery. J. Surg. Oncol., 48: 39-44, 1991.
26. Piver S.M., Lele S.B., Marchetti D.L., Baker T.R., Tsudada Y., Einrich L.J.: The impact of aggressive debulking surgery and cisplatin based chemotherapy on progression free survival in stage III and IV ovarian carcinoma J. Clin. Oncol., 6: 983-989, 1988.
27. Piver M.S., Baker T.R., Driscoll D.L.: Lack of substantial five year disease free survival by primary aggressive surgery and cisplatin based chemotherapy or by salvage intraperitoneal cisplatin based chemotherapy. Eur. J. Gynaecol. Oncol., 10: 243-250, 1990.
28. Piver M.S., Lele S.B., Marchetti D.L., Baker T.R., Emrich L.J., Hartman A.B.: Surgically documented response to intraperitoneal cisplatin, cytarabine and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J. Clin. Oncol., 6: 1679-1684, 1988.
29. Reichman B., Markman M., Hakes T., Hoskins W., Rubin S., Jones W., Almadrones L., Ochoa M., Chapman D., Saigo P., Lewis J.L.: Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J. Clin. Oncol., 7: 1327-1332, 1990.
30. Runowicz C.D., Dottino P.R., Shafir M.K., Mark M.A., Cohen C.J.: Catheter complications associated with intraperitoneal chemotherapy. Gynec. Oncol., 24: 41-50, 1986.
31. Spayer L.J., Beller U., Colombo N.: Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J. Clin. Oncol., 8: 1335-1341, 1990.